Related Experiment Videos
Effects of neonatal antithyroid treatment on brain [3H]-imipramine binding sites
Abstract:
The action of the antithyroid, sulphydryl reagent methimazole (MMI) on the specific binding of [3H]-imipramine in the cerebral cortex and corpus striatum of immature and mature rats has been examined. Chronic administration of MMI through the first 30 days of life decreased the number of imipramine binding sites in cortical but not striatal membranes, as assessed 48 h after the last injection of goitrogen. A similar treatment did not affect the binding profile of [3H]-imipramine in mature rats. Acute administration of MMI to 30 day-old rats increased the number of imipramine binding sites shortly after the injection, an effect no longer evident 48 h later. MMI in vitro increased the binding of [3H]-imipramine. It is concluded that maturational impairment of the hypothyroid cortex, rather than any alteration of membrane bound thiol groups, was a major cause for the diminished binding of [3H]-imipramine in MMI-treated, immature rats.
Insights
Methimazole (MMI) impacts imipramine binding sites in developing rat brains. Chronic MMI exposure reduced cortical binding in immature rats, suggesting maturational impairment affects neurochemical development.
Area of Science:
- Neuropharmacology
- Developmental Neuroscience
- Endocrinology
Background:
- Methimazole (MMI) is an antithyroid drug that acts as a sulphydryl reagent.
- Imipramine binding sites are crucial targets for understanding neurotransmitter reuptake mechanisms.
- Thyroid hormones play a significant role in brain development and maturation.
Purpose of the Study:
- To investigate the effect of methimazole (MMI) on [3H]-imipramine binding in immature and mature rat brains.
- To determine if MMI-induced hypothyroidism alters imipramine binding site density.
- To differentiate between direct MMI effects and hypothyroidism-induced changes on imipramine binding.
Main Methods:
- Administration of methimazole (MMI) to immature (30-day-old) and mature rats.
- Chronic and acute MMI treatment protocols were employed.
- Measurement of specific [3H]-imipramine binding in cerebral cortex and corpus striatum membrane preparations.
- In vitro incubation of MMI with brain membranes to assess direct effects.
Main Results:
- Chronic MMI administration to immature rats decreased imipramine binding sites in cortical membranes but not striatal membranes.
- Mature rats treated chronically with MMI showed no significant changes in imipramine binding.
- Acute MMI administration to immature rats transiently increased imipramine binding sites.
- In vitro, MMI enhanced [3H]-imipramine binding.
Conclusions:
- The reduction in [3H]-imipramine binding in MMI-treated immature rats is primarily attributed to maturational impairment of the hypothyroid cortex.
- Alterations in membrane-bound thiol groups are unlikely to be the main cause of diminished imipramine binding.
- Developmental stage significantly influences the brain's response to antithyroid drug exposure.